Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS

Mohamad Irani, Howard Minkoff, David Seifer, Zaher Merhi

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Context: Elevation of serum proinflammatory advanced glycation end products (AGEs) is involved in the pathogenesis of polycystic ovary syndrome (PCOS). The soluble receptor for AGEs (sRAGE) acts as a decoy by binding circulating AGEs. Vitamin D supplementation attenuates the deposition of AGEs in the vascular system of diabetic animals and improves some metabolic aspects of vitamin D-deficient women with PCOS. Additionally, serum anti-Mullerian hormone (AMH) is elevated in women with PCOS, reflecting abnormal ovarian folliculogenesis. Objective: The objective of the study was to evaluate the effect of 1,25 dihydroxyvitamin D3 (vit D3) supplementation on serum sRAGE and AMH in vitamin D-deficient women with PCOS. Design, Settings, Participants, and Intervention: Sixty-seven women with (n = 22) or without (control; n = 45) PCOS who were diagnosed with vitamin D deficiency were enrolled. Fifty-one women were replaced with oral vit D3 for 8 weeks (16 with PCOS and 35 controls) and 16 women were not treated (six with PCOS and 10 controls). Serum 25-hydroxyvitamin D (25 OH-D), sRAGE, and AMH concentrations were measured at baseline and after vit D3 supplementation in the treated group and 8 weeks apart in the nontreated group. Main Outcome Measure(s): Changes in serum sRAGE and AMH concentrations after vit D3 replacement were measured. Results: In all participants, there was a negative correlation between body mass index and serum sRAGE levels (r=-0.3, P = .01). In women with PCOS, but not in controls, vit D3 increased serum sRAGE (P=.03) and decreased serumAMHlevels (P

Original languageEnglish (US)
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Vitamin D
Anti-Mullerian Hormone
Serum
Advanced Glycosylation End Products
Calcitriol
Vitamin D Deficiency
Advanced Glycosylation End Product-Specific Receptor
Animals
Blood Vessels
Body Mass Index
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. / Irani, Mohamad; Minkoff, Howard; Seifer, David; Merhi, Zaher.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 5, 2014.

Research output: Contribution to journalArticle

@article{09252647e08a42c7b907aac869357246,
title = "Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS",
abstract = "Context: Elevation of serum proinflammatory advanced glycation end products (AGEs) is involved in the pathogenesis of polycystic ovary syndrome (PCOS). The soluble receptor for AGEs (sRAGE) acts as a decoy by binding circulating AGEs. Vitamin D supplementation attenuates the deposition of AGEs in the vascular system of diabetic animals and improves some metabolic aspects of vitamin D-deficient women with PCOS. Additionally, serum anti-Mullerian hormone (AMH) is elevated in women with PCOS, reflecting abnormal ovarian folliculogenesis. Objective: The objective of the study was to evaluate the effect of 1,25 dihydroxyvitamin D3 (vit D3) supplementation on serum sRAGE and AMH in vitamin D-deficient women with PCOS. Design, Settings, Participants, and Intervention: Sixty-seven women with (n = 22) or without (control; n = 45) PCOS who were diagnosed with vitamin D deficiency were enrolled. Fifty-one women were replaced with oral vit D3 for 8 weeks (16 with PCOS and 35 controls) and 16 women were not treated (six with PCOS and 10 controls). Serum 25-hydroxyvitamin D (25 OH-D), sRAGE, and AMH concentrations were measured at baseline and after vit D3 supplementation in the treated group and 8 weeks apart in the nontreated group. Main Outcome Measure(s): Changes in serum sRAGE and AMH concentrations after vit D3 replacement were measured. Results: In all participants, there was a negative correlation between body mass index and serum sRAGE levels (r=-0.3, P = .01). In women with PCOS, but not in controls, vit D3 increased serum sRAGE (P=.03) and decreased serumAMHlevels (P",
author = "Mohamad Irani and Howard Minkoff and David Seifer and Zaher Merhi",
year = "2014",
doi = "10.1210/jc.2013-4374",
language = "English (US)",
volume = "99",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS

AU - Irani, Mohamad

AU - Minkoff, Howard

AU - Seifer, David

AU - Merhi, Zaher

PY - 2014

Y1 - 2014

N2 - Context: Elevation of serum proinflammatory advanced glycation end products (AGEs) is involved in the pathogenesis of polycystic ovary syndrome (PCOS). The soluble receptor for AGEs (sRAGE) acts as a decoy by binding circulating AGEs. Vitamin D supplementation attenuates the deposition of AGEs in the vascular system of diabetic animals and improves some metabolic aspects of vitamin D-deficient women with PCOS. Additionally, serum anti-Mullerian hormone (AMH) is elevated in women with PCOS, reflecting abnormal ovarian folliculogenesis. Objective: The objective of the study was to evaluate the effect of 1,25 dihydroxyvitamin D3 (vit D3) supplementation on serum sRAGE and AMH in vitamin D-deficient women with PCOS. Design, Settings, Participants, and Intervention: Sixty-seven women with (n = 22) or without (control; n = 45) PCOS who were diagnosed with vitamin D deficiency were enrolled. Fifty-one women were replaced with oral vit D3 for 8 weeks (16 with PCOS and 35 controls) and 16 women were not treated (six with PCOS and 10 controls). Serum 25-hydroxyvitamin D (25 OH-D), sRAGE, and AMH concentrations were measured at baseline and after vit D3 supplementation in the treated group and 8 weeks apart in the nontreated group. Main Outcome Measure(s): Changes in serum sRAGE and AMH concentrations after vit D3 replacement were measured. Results: In all participants, there was a negative correlation between body mass index and serum sRAGE levels (r=-0.3, P = .01). In women with PCOS, but not in controls, vit D3 increased serum sRAGE (P=.03) and decreased serumAMHlevels (P

AB - Context: Elevation of serum proinflammatory advanced glycation end products (AGEs) is involved in the pathogenesis of polycystic ovary syndrome (PCOS). The soluble receptor for AGEs (sRAGE) acts as a decoy by binding circulating AGEs. Vitamin D supplementation attenuates the deposition of AGEs in the vascular system of diabetic animals and improves some metabolic aspects of vitamin D-deficient women with PCOS. Additionally, serum anti-Mullerian hormone (AMH) is elevated in women with PCOS, reflecting abnormal ovarian folliculogenesis. Objective: The objective of the study was to evaluate the effect of 1,25 dihydroxyvitamin D3 (vit D3) supplementation on serum sRAGE and AMH in vitamin D-deficient women with PCOS. Design, Settings, Participants, and Intervention: Sixty-seven women with (n = 22) or without (control; n = 45) PCOS who were diagnosed with vitamin D deficiency were enrolled. Fifty-one women were replaced with oral vit D3 for 8 weeks (16 with PCOS and 35 controls) and 16 women were not treated (six with PCOS and 10 controls). Serum 25-hydroxyvitamin D (25 OH-D), sRAGE, and AMH concentrations were measured at baseline and after vit D3 supplementation in the treated group and 8 weeks apart in the nontreated group. Main Outcome Measure(s): Changes in serum sRAGE and AMH concentrations after vit D3 replacement were measured. Results: In all participants, there was a negative correlation between body mass index and serum sRAGE levels (r=-0.3, P = .01). In women with PCOS, but not in controls, vit D3 increased serum sRAGE (P=.03) and decreased serumAMHlevels (P

UR - http://www.scopus.com/inward/record.url?scp=84899972594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899972594&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-4374

DO - 10.1210/jc.2013-4374

M3 - Article

C2 - 24606102

AN - SCOPUS:84899972594

VL - 99

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -